Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Cost-Effectiveness Analysis of Posaconazole versus Liposomal Amphotericin B in the Treatment of Mucormycosis patients in Iran

  • In: Poster Presentation
  • At: Stockholm (Sweden) (2017)
  • Type: Poster
  • Poster code: P-D-022-Monday
  • By: TAHERI, Saeed (Shahid Beheshti University of Medical Science, Dept. of pharmacoeconomics and Pharma Management, Tehran, Iran, Islamic Republic Of)
  • Co-author(s): Saeed Taheri: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Leila Zarei: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Alireza Ghiamat: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Gholamhossein Mehralian: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
  • Abstract:

    Backgrounds

    Mucormycosis is an invasive fungal infection with high mortality specially in decompensated diabetics and immunosuppressed patients. The Mucorales are inherently resistant to most widely used antifungal agents. Liposomal Amphotericin B (AmB) is an appropriate option for empirical therapy, whereas Posaconazole (PCZ), a new..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses